IRLA Stock Forecast: IRulya Therapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering IRulya Therapeutics, Inc. hold a median 12-month price target of $71 — +78.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores IRulya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (14): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IRLA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IRLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +78.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | Cantor Fitzgerald | Reiterates | Overweight | $70 |
| 16 Nov 2026 | Citizens | Maintains | Market Outperform | $77 → $86 |
| 9 Oct 2026 | Raymond James | Initiates | Outperform | $72 |
| 24 Sept 2026 | Rodman & Renshaw | Initiates | Buy | $70 |
| 22 Sept 2026 | Citizens | Upgrade | Market Outperform | $77 |
| 18 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $70 |
| 29 July 2026 | Oppenheimer | Initiates | Outperform | $82 |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | $4.00 |
| 23 June 2026 | Cantor Fitzgerald | Initiates | Overweight | $4.00 |
| 30 Jan 2026 | Citizens | Downgrade | Market Perform | — |
| 30 Jan 2026 | D. Boral Capital | Downgrade | Hold | — |
| 29 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 5 Aug 2025 | JMP Securities | Initiates | Market Outperform | — |
| 17 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 June 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRLA.
This page is one stock. Monday covers all of them.
IRLA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IRLA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, IRulya Therapeutics, Inc. returned −90.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IRLA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −37.2%
- Dividend yield
- —
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IRulya Therapeutics, Inc. has a market value of $432.4M and an enterprise value of $465.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.5M.
Free cash flow in the twelve months to 30 June 2026: −$47.0M.
IRulya Therapeutics, Inc. employs 38 people.
Data provided by Twelve Data
IRLA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IRLA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own IRulya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IRLA
What is the IRLA stock price forecast for 2026-2027?
The 8 Wall Street analysts covering IRulya Therapeutics, Inc. have a median 12-month price target of $71, with estimates ranging from $65 to $98. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IRLA stock a buy right now?
Of the 8 analysts covering IRulya Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRulya Therapeutics, Inc. 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IRLA?
As at 21 Nov 2026, IRulya Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
Will IRLA stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +78.0% from the last close, and Ticker Nerd's factor model ranks IRulya Therapeutics, Inc. 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IRLA stock forecast for 2030?
No analyst covering IRulya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $98 over the next 12 months.
How has IRLA stock performed over the past year?
IRulya Therapeutics, Inc. returned -90.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does IRulya Therapeutics, Inc. do?
IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious and underserved pulmonary conditions. Its primary program, LAM-001, is an investigational inhaled dry-powder formulation of rapamycin designed to address pulmonary diseases associated with dysregulated mammalian target of rapamycin activity.
About IRulya Therapeutics, Inc.
IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious and underserved pulmonary conditions. Its primary program, LAM-001, is an investigational inhaled dry-powder formulation of rapamycin designed to address pulmonary diseases associated with dysregulated mammalian target of rapamycin activity. Current development areas include pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome following lung transplantation, and sarcoidosis-associated pulmonary hypertension. The company’s work combines drug formulation, inhalation delivery, and targeted clinical development to support potential treatments for complex respiratory disorders. IRulya Therapeutics Inc. operates within the biotechnology and specialty pharmaceuticals markets, serving an area where conventional treatment options may not adequately address underlying disease mechanisms. Its business is centered on advancing proprietary therapeutic candidates through clinical research and regulatory development, positioning the company as a focused participant in the pulmonary medicine sector.
CEO Dr. Brigette Roberts M.D. · 38 employees · United States · https://irulya.com